首页> 外文期刊>Journal of Breast Cancer >Changes of Coregulators, MAP Kinase Activity and p27/kip1 with Estrogen or Antiestrogen Treatment in Breast Cancer Cell Line
【24h】

Changes of Coregulators, MAP Kinase Activity and p27/kip1 with Estrogen or Antiestrogen Treatment in Breast Cancer Cell Line

机译:雌激素或抗雌激素治疗乳腺癌细胞株中的调节剂,MAP激酶活性和p27 / kip1的变化

获取原文
           

摘要

Purpose Estrogen, various polypeptide hormones and growth factors are associated with the development and progression of breast cancer. Coregulatory proteins are also associated with estrogen receptor (ER) transcriptional activity and tamoxifen resistance. Therefore, it is necessary to investigate the change of coregulator mRNAs and various cell proliferation proteins and cell cycle-related proteins after treatment with estrogen or antiestrogen. Methods MCF-7 cells were maintained in dextran-coated charcoal stripped 10% Dulbecco's Modified Eagle Medium (DMEM). To measure the change of the coactivators' (src- 1, P/CAF, CBP, AIB1) mRNAs and corepressors' (SMRT, N-coR) mRNAs, multiple PCR was carried out using specific primers. In addition, intracellular proteins related to cell proliferation and cell cycle regulation were measured by performing Western blotting after treatment with estrogen or tamoxifen. The change of mitogen activated protein kinases was also measured by performing Western after tamoxifen treatment for 4 weeks. Results Coactivator mRNAs expression rapidly decreased in 15 min after estrogen treatment but this recovered to the initial level in 3 hr. The pattern was similar for the case of tamoxifen treatment. Corepressor mRNAs expression rapidly decreased in 15 min after estrogen treatment and it remained at a lower level until 24 hr after estrogen treatment. With tamoxifen treatment, the initial response was similar to the cases of estrogen treatment, but the expression gradually increased 3 hr after tamoxifen treatment. Treatment of estrogen induced intracellular concentrations of c-myc and Ki-67 and it increased nuclear translocation of NF-κB and phosphor-ERK and it decreased the intracellular cell cycle suppressor p27/kip1. Tamoxifen treatment increased nuclear p27/kip1 but it decreased c-myc, NF-κB and phosphor-ERK. Long-term (4 weeks) treatment of tamoxifen was associated with decrease of activated ERK and p38 but there was no change in phospho-Akt level. Conclusion Estrogen induced cell proliferation and the survival pathway-related factors, but it decreased the cell cycle suppressor p27/kip1. Long-term treatment with antiestrogen tamoxifen might decrease the MAPK activities in ERα-expressing tumor cells.
机译:目的雌激素,各种多肽激素和生长因子与乳腺癌的发生发展有关。调控蛋白还与雌激素受体(ER)转录活性和他莫昔芬抗性有关。因此,有必要研究雌激素或抗雌激素治疗后共调节因子mRNA和各种细胞增殖蛋白及细胞周期相关蛋白的变化。方法将MCF-7细胞保存在葡聚糖包被的木炭中,该木炭经剥离的10%Dulbecco改良Eagle培养基(DMEM)中。为了测量共激活因子(src-1,P / CAF,CBP,AIB1)mRNA和共加压因子(SMRT,N-coR)mRNA的变化,使用特异性引物进行了多次PCR。另外,在用雌激素或他莫昔芬处理后,通过进行蛋白质印迹来测量与细胞增殖和细胞周期调节有关的细胞内蛋白。还通过他莫昔芬治疗4周后进行Western测定了促分裂原活化蛋白激酶的变化。结果雌激素处理后15min内Coactivator mRNA的表达迅速下降,但3小时后恢复到初始水平。他莫昔芬治疗的情况与此相似。在雌激素治疗后15分钟内,corepressor mRNA的表达迅速下降,直到雌激素治疗后24小时一直保持较低水平。他莫昔芬治疗的初始反应与雌激素治疗相似,但在他莫昔芬治疗3小时后其表达逐渐增加。雌激素的治疗​​诱导了细胞内c-myc和Ki-67的浓度,并增加了NF-κB和磷-ERK的核转运,并降低了细胞内细胞周期抑制剂p27 / kip1。他莫昔芬治疗增加了核p27 / kip1,但降低了c-myc,NF-κB和磷-ERK。他莫昔芬的长期治疗(4周)与活化的ERK和p38的降低有关,但磷酸化Akt水平没有变化。结论雌激素可诱导细胞增殖及与生存途径相关的因子,但能降低细胞周期抑制因子p27 / kip1。他莫昔芬抗雌激素的长期治疗可能会降低表达ERα的肿瘤细胞中的MAPK活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号